Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 3726

Drug Profile

MEDI 3726

Alternative Names: ADCT 401; MEDI-3726

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics
  • Developer ADC Therapeutics; MedImmune
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 30 Sep 2019 MedImmune completes a phase I trial in Prostate cancer (Metastatic disease; Second line therapy or greater) in USA (Parenteral) (NCT02991911)
  • 25 Jul 2019 Discontinued - Phase-I for Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA (Parenteral) before July 2019 due to safety and efficacy issues (NCT02264678) (Astrazeneca pipeline, July 2019)
  • 15 Aug 2018 MedImmune re-initiates phase I trial in Prostate cancer (Metastatic disease; Second line therapy or greater) in USA (NCT02991911)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top